Published • loading... • Updated
Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus
Summary by ts2.tech
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus
Novavax shares jumped 13% Friday after first-quarter revenue reached $139.5 million, beating estimates. Licensing and partner payments, including $30 million from Pfizer’s Matrix-M deal, offset weak COVID-19 vaccine demand. The stock traded at $10.45 with volume over 8.4 million shares. Investors await the company’s appearance at BofA’s health-care conference on May 13. The post Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Bac…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
